How Psychedelics and Brain Stimulation Are Rewiring Depression and PTSD
Dr. Nolan Williams explores TMS, psilocybin, MDMA, ibogaine, and ayahuasca as transformative treatments for depression and PTSD.
975 articles in this topic
Dr. Nolan Williams explores TMS, psilocybin, MDMA, ibogaine, and ayahuasca as transformative treatments for depression and PTSD.
A completed Phase 1 trial compared the abuse liability of rapastinel versus ketamine in recreational polydrug users, with implications for safer depression treatment.
A structured neuroplasticity-based program improved functional performance and emotional well-being in community-dwelling older adults with dementia.
Losing a key cholinergic peptide dramatically worsens memory in Alzheimer's mice, pointing to a overlooked pathway in cognitive decline.
New research shows tau pathology disrupts neuronal cargo transport before tangles form — and a kinase inhibitor can reverse it.
Prolonged sleep duration and later wake times predict faster cognitive decline, especially in older adults with amyloid and tau buildup.
A surprising new role for brain immune cells: microglia orchestrate glucose delivery to fuel memory-forming protein synthesis in active neurons.
Researchers restored a key brain circuit in mice and reversed anxiety and social withdrawal, pointing to a powerful new therapeutic target.
A Japanese RCT shows tenecteplase (0.25 mg/kg) achieves 3x higher early recanalization than low-dose alteplase (0.6 mg/kg) in LVO stroke patients.
Researchers pinpoint a brainstem pathway linking vagal signals to pain suppression and mood, explaining how VNS therapy works.
A landmark study links epigenetic patterns at birth to infant gut microbiome development, with certain bacteria reducing neurodevelopmental risk by age three.
A double-blind trial tests whether 810nm photobiomodulation can reverse cognitive impairment in long COVID patients at home.